KN8.F KRKA D.D. A NA

Healthcare Drug Manufacturers - Specialty & Generic Frankfurt Exchange
245.50 EUR
Close of Nov 13, 2026
181.99 300.00
Market cap
EUR 7.43B
P/E
17.8x
P/B
2.89x
ROE
19.9%
Dividend yield
3.39%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is KN8.F undervalued?

Graham number
Price245.50
Graham value162.20
Premium51.4%

KN8.F trades 51.4% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

KRKA D.D. A NA fundamental analysis

No fundamental analysis for KRKA D.D. A NA yet.

KRKA D.D. A NA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About KRKA D.D. A NA

Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company offers prescription pharmaceuticals for cardiovascular, central nervous system, gastrointestinal tract, pain, diabetes, and other therapeutic areas. It also provides non-prescription products for cough,…

Full company profile